Surgery Partners, Inc. (NASDAQ: SGRY) stands as a notable player within the healthcare sector, specifically in the medical care facilities industry. With a market capitalization of $2 billion, this Brentwood, Tennessee-based company operates a network of surgical facilities and ancillary services across the United States. Its offerings include ambulatory surgery centers and surgical hospitals, focusing on specialties such as orthopedics, pain management, ophthalmology, and gastroenterology.
### Price and Valuation Snapshot
As of the latest trading session, SGRY’s stock price hovers at $15.46, showing negligible movement with a price change of -0.03, or 0.00%. The stock has experienced a 52-week range between $13.43 and $25.85, suggesting some volatility and a broad trading spectrum. The company’s forward P/E ratio stands at 22.46, although the trailing P/E, PEG ratio, and other valuation metrics such as Price/Book and Price/Sales remain unreported.
### Performance Metrics and Financial Health
Surgery Partners has demonstrated a revenue growth of 6.60%, a respectable figure in a competitive industry. However, its financial performance paints a mixed picture. The reported EPS is -1.36, indicating that the company is not currently generating positive earnings per share. Net income figures are not available, and return on equity is a modest 0.66%. Despite these challenges, the company boasts a strong free cash flow of over $131 million, suggesting liquidity strength and operational efficiency.
### Dividend and Payout Insights
For income-focused investors, it’s important to note that Surgery Partners does not offer a dividend yield, with a payout ratio of 0.00%. This indicates that the company is potentially reinvesting its earnings back into growth opportunities rather than returning capital to shareholders.
### Analyst Ratings and Potential Upside
The sentiment from analysts is predominantly positive. Out of the total ratings, 9 are Buy ratings, 3 are Hold, and there are no Sell recommendations. The target price range for SGRY is between $18.00 and $33.00, with an average target price of $25.45. This represents a significant potential upside of 64.65% from the current price, highlighting the optimism among analysts regarding the stock’s future performance.
### Technical Indicators
The technical analysis of SGRY reveals some critical insights. The 50-day moving average is slightly above the current price at $15.55, while the 200-day moving average is considerably higher at $20.04, indicating potential resistance levels. The Relative Strength Index (RSI) at 18.44 suggests that the stock is in oversold territory, which could signal a buying opportunity for contrarian investors. Additionally, the MACD at -0.29 with a signal line of -0.43 might indicate bearish momentum, warranting cautious optimism.
### Conclusion
For investors considering Surgery Partners, Inc., the stock presents an intriguing blend of potential and risk. The significant upside potential, as suggested by analyst targets, is counterbalanced by current earnings challenges and mixed technical indicators. As a company well-positioned in the growing healthcare sector, SGRY might appeal to investors with a risk appetite for growth stocks underpinned by strong cash flow. However, market participants should conduct thorough due diligence and consider the broader market dynamics before making investment decisions.
